Tarek Alhamad

Tarek Alhamad, MD, MS

  • Kidney Health (Nephrology)

Sees Patients For

Antibody mediated rejection, simultaneous pancreas and kidney transplantation, high risk kidney transplantation, recurrent glomerulonephritis.

Patients Seen At

Hospital Affiliations

  • Barnes-Jewish Hospital

Board Certifications

  • Internal Medicine
  • Nephrology

Academic Title(s)

Associate Professor, Medicine
Division of Nephrology

Languages

  • English

Education

Fellowship, Transplant Nephrology

2014 Mayo Clinic, Scottsdale, AZ

Fellowship, General Nephrology

2013 Penn State College of Medicine, Penn State University, Hershey, PA

MS, Public Health Science

2013 Penn State University, Hershey, PA

Residency, Internal Medicine

2011 Texas Tech University Health Sciences Center, El Paso, TX

Medical Degree

2005 University of Damascus, Damascus, Syria

Publications & Research

Search PubMed for publications »

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Company Name: VeloxisRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $1 - $9,999Speaker Fees: $10,000 - $19,999Reporting Date: 05/01/2020
Company Name: CareDXRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $1 - $9,999Speaker Fees: $10,000 - $19,999Reporting Date: 05/01/2020
Company Name: VeloxisRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $1 - $9,999Speaker Fees: $10,000 - $19,999Reporting Date: 05/01/2020
Company Name: Mallinckrodt PharmaceuticalsRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $10,000 - $19,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2020
Company Name: PaladinRoyalties: $1 - $9,999Equity: YesConsulting/Advisory Board: $1 - $9,999Speaker Fees: $20,000 - $39,999Reporting Date: 05/01/2020